by Gilles Rubinstenn | Nov 7, 2022 | News
On October 11, 2022, the USPTO issued ReST Therapeutics a patent on the use of its drug candidate FENM for the treatment of anxiety and PTSD. ReST Therapeutics’ project is to develop a proprietary drug candidate for the treatment of Post-Traumatic Syndrome and...
by Gilles Rubinstenn | Jun 15, 2022 | News
On May 6, the National Institute of Intellectual Property (INPI) issued ReST Therapeutics and its academic co-owners (University of Montpellier, INSERM, and the Ecole Pratique des Hautes Etudes) a patent on neuroprotection. ReST Therapeutics’ project is to...
by Gilles Rubinstenn | Jul 22, 2021 | News
Biological Psychiatry Published: May 09, 2021DOI: https://doi.org/10.1016/j.biopsych.2021.04.024 Fluoroethylnormemantine, a Novel NMDA Receptor Antagonist, for the Prevention and Treatment of Stress-Induced Maladaptive Behavior. Briana K.Chen, Victor M.Luna, Margaret...
by Gilles Rubinstenn | Jul 22, 2021 | News
International Journal of Neuropsychopharmacology, 2021 Jul 14;24(6):519-531. https://doi.org/10.1093/ijnp/pyab007 Fluoroethylnormemantine, A Novel Derivative of Memantine, Facilitates Extinction Learning WithoutSensorimotor Deficits. Briana K. Chen, Gwenaëlle Le Pen,...
by Gilles Rubinstenn | Dec 4, 2020 | News
Dr. Tangui Maurice of Montpellier University and ReST’s scientific partner will present FENM results on Alzheimer during the upcoming 15th International Conference on Alzheimer’s and Parkinson’s Diseases: Mechanisms, Clinical Strategies and promising Treatments...
by Gilles Rubinstenn | Sep 29, 2020 | News
International Journal of Neuropsychopharmacology (2020) XX(XX): 1–16; pyaa075, https://doi.org/10.1093/ijnp/pyaa075 Anti-Amnesic and Neuroprotective Effects of Fluoroethylnormemantine in a Pharmacological Mouse Model of Alzheimer’s Disease. Simon Couly, Morgane...
